All Studies Meta Analysis Recent:

Protective Effect of Fluvoxamine for COVID-19 in Obsessive-Compulsive Disorder

Diaz et al., The Primary Care Companion For CNS Disorders, doi:10.4088/PCC.22br03337

Oct 2022

Post
Facebook

Source PDF All Meta

Fluvoxamine

26th treatment shown to reduce risk in November 2021

^*, now known with p = 0.00014 from 21 studies, recognized in 3 countries.

Lower risk for mortality, hospitalization, progression, recovery, and cases.

No treatment is 100% effective. Protocols combine complementary and synergistic treatments. ^* >10% efficacy in meta analysis with ≥3 clinical studies.

4,100+ studies for 60+ treatments. c19early.org

TriNetX PSM retrospective 82,069 OCD patients, showing lower risk of COVID-19 with fluvoxamine use.

Important missing comments or errors? Let us know.

risk of case, 28.0% lower, OR 0.72, p < 0.001, treatment 4,558, control 4,558, propensity score matching, RR approximated with OR.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Diaz et al., 6 Oct 2022, retrospective, USA, peer-reviewed, 2 authors.

This Paper Fluvoxamine All

Download Image

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0